283 related articles for article (PubMed ID: 34268531)
1. Bulevirtide for HBV and HDV infections.
Yardeni D; Koh C
Drugs Today (Barc); 2021 Jul; 57(7):433-448. PubMed ID: 34268531
[TBL] [Abstract][Full Text] [Related]
2. Future treatments for hepatitis delta virus infection.
Asselah T; Loureiro D; Tout I; Castelnau C; Boyer N; Marcellin P; Mansouri A
Liver Int; 2020 Feb; 40 Suppl 1():54-60. PubMed ID: 32077603
[TBL] [Abstract][Full Text] [Related]
3. Reduced hepatitis B and D viral entry using clinically applied drugs as novel inhibitors of the bile acid transporter NTCP.
Donkers JM; Zehnder B; van Westen GJP; Kwakkenbos MJ; IJzerman AP; Oude Elferink RPJ; Beuers U; Urban S; van de Graaf SFJ
Sci Rep; 2017 Nov; 7(1):15307. PubMed ID: 29127322
[TBL] [Abstract][Full Text] [Related]
4. [Bulevirtide as the first specific agent against hepatitis D virus infections-mechanism and clinical effect].
Nkongolo S; Hollnberger J; Urban S
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2022 Feb; 65(2):254-263. PubMed ID: 35028672
[TBL] [Abstract][Full Text] [Related]
5. Assembly and infection efficacy of hepatitis B virus surface protein exchanges in 8 hepatitis D virus genotype isolates.
Wang W; Lempp FA; Schlund F; Walter L; Decker CC; Zhang Z; Ni Y; Urban S
J Hepatol; 2021 Aug; 75(2):311-323. PubMed ID: 33845061
[TBL] [Abstract][Full Text] [Related]
6. Interactions of Na
Zakrzewicz D; Geyer J
Biol Chem; 2023 Jun; 404(7):673-690. PubMed ID: 37103224
[TBL] [Abstract][Full Text] [Related]
7. New therapies for hepatitis delta virus infection.
Loureiro D; Castelnau C; Tout I; Boyer N; Narguet S; Menasria Benazzouz S; Louis Z; Pons-Kerjean N; Giuly N; Marcellin P; Mansouri A; Asselah T
Liver Int; 2021 Jun; 41 Suppl 1():30-37. PubMed ID: 34155804
[TBL] [Abstract][Full Text] [Related]
8. A Novel Tricyclic Polyketide, Vanitaracin A, Specifically Inhibits the Entry of Hepatitis B and D Viruses by Targeting Sodium Taurocholate Cotransporting Polypeptide.
Kaneko M; Watashi K; Kamisuki S; Matsunaga H; Iwamoto M; Kawai F; Ohashi H; Tsukuda S; Shimura S; Suzuki R; Aizaki H; Sugiyama M; Park SY; Ito T; Ohtani N; Sugawara F; Tanaka Y; Mizokami M; Sureau C; Wakita T
J Virol; 2015 Dec; 89(23):11945-53. PubMed ID: 26378168
[TBL] [Abstract][Full Text] [Related]
9. Sodium taurocholate cotransporting polypeptide acts as a receptor for hepatitis B and D virus.
Yan H; Li W
Dig Dis; 2015; 33(3):388-96. PubMed ID: 26045274
[TBL] [Abstract][Full Text] [Related]
10. Beyond bulevirtide: Alternative therapeutic options for the management of hepatitis delta virus.
Asselah T
J Viral Hepat; 2023 Apr; 30 Suppl 1():33-38. PubMed ID: 36529713
[TBL] [Abstract][Full Text] [Related]
11. Primary biliary acids inhibit hepatitis D virus (HDV) entry into human hepatoma cells expressing the sodium-taurocholate cotransporting polypeptide (NTCP).
Veloso Alves Pereira I; Buchmann B; Sandmann L; Sprinzl K; Schlaphoff V; Döhner K; Vondran F; Sarrazin C; Manns MP; Pinto Marques Souza de Oliveira C; Sodeik B; Ciesek S; von Hahn T
PLoS One; 2015; 10(2):e0117152. PubMed ID: 25646622
[TBL] [Abstract][Full Text] [Related]
12. Long-term
Lowjaga KAAT; Kirstgen M; Müller SF; Goldmann N; Lehmann F; Glebe D; Geyer J
Am J Physiol Gastrointest Liver Physiol; 2021 Jan; 320(1):G66-G80. PubMed ID: 33174454
[TBL] [Abstract][Full Text] [Related]
13. [Delta hepatitis: Epidemiology, diagnostic, natural history and treatment].
Loureiro D; Castelnau C; Bed CM; Asselah T
Rev Med Interne; 2022 Mar; 43(3):160-169. PubMed ID: 34799189
[TBL] [Abstract][Full Text] [Related]
14. Bulevirtide and emerging drugs for the treatment of hepatitis D.
Xu HY; Yang JO; Chen PH; Han SB
Expert Opin Biol Ther; 2023; 23(12):1245-1253. PubMed ID: 37853604
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis D virus: Improving virological knowledge to develop new treatments.
Khalfi P; Kennedy PT; Majzoub K; Asselah T
Antiviral Res; 2023 Jan; 209():105461. PubMed ID: 36396025
[TBL] [Abstract][Full Text] [Related]
16. Bulevirtide monotherapy for 48 weeks in patients with HDV-related compensated cirrhosis and clinically significant portal hypertension.
Degasperi E; Anolli MP; Uceda Renteria SC; Sambarino D; Borghi M; Perbellini R; Scholtes C; Facchetti F; Loglio A; Monico S; Fraquelli M; Costantino A; Ceriotti F; Zoulim F; Lampertico P
J Hepatol; 2022 Dec; 77(6):1525-1531. PubMed ID: 35973578
[TBL] [Abstract][Full Text] [Related]
17. Molecular determinants of hepatitis B and D virus entry restriction in mouse sodium taurocholate cotransporting polypeptide.
Yan H; Peng B; He W; Zhong G; Qi Y; Ren B; Gao Z; Jing Z; Song M; Xu G; Sui J; Li W
J Virol; 2013 Jul; 87(14):7977-91. PubMed ID: 23678176
[TBL] [Abstract][Full Text] [Related]
18. Treatment of Chronic Hepatitis D with Bulevirtide-A Fight against Two Foes-An Update.
Ferenci P; Reiberger T; Jachs M
Cells; 2022 Nov; 11(22):. PubMed ID: 36428959
[TBL] [Abstract][Full Text] [Related]
19. Excellent safety and effectiveness of high-dose myrcludex-B monotherapy administered for 48 weeks in HDV-related compensated cirrhosis: A case report of 3 patients.
Loglio A; Ferenci P; Uceda Renteria SC; Tham CYL; van Bömmel F; Borghi M; Holzmann H; Perbellini R; Trombetta E; Giovanelli S; Greco L; Porretti L; Prati D; Ceriotti F; Lunghi G; Bertoletti A; Lampertico P
J Hepatol; 2019 Oct; 71(4):834-839. PubMed ID: 31302176
[TBL] [Abstract][Full Text] [Related]
20. Blocking viral entry with bulevirtide reduces the number of HDV-infected hepatocytes in human liver biopsies.
Allweiss L; Volmari A; Suri V; Wallin JJ; Flaherty JF; Manuilov D; Downie B; Lütgehetmann M; Bockmann JH; Urban S; Wedemeyer H; Dandri M
J Hepatol; 2024 Jun; 80(6):882-891. PubMed ID: 38340811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
